Thirty four patients who developed anaemia (Hb level ≤ 11 g/dL) among the 319 (11%) GIST patients treated with imatinib in clinical trials or with compassionate use in the 4 French centres, between July 2001 and August 2003, received EPO therapy. Here, GSTM1 is linked to anemia.